Differences in local versus systemic TNFα production in COPD: Inhibitory effect of hyaluronan on LPS induced blood cell TNFα release

Thorax

Volumn 61, Issue 6, 2006, Pages 478-484

  Dentener, M A ^a,b   Louis, R ^c   Cloots, R H E ^b   Henket, M ^c   Wouters, E F M ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; PRIORITY JOURNAL; SPUTUM;

ADULT; AGED; BLOOD CELLS; BRONCHITIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYALURONIC ACID; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA; VITAL CAPACITY;

EID: 33745150041     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.053330     Document Type: Article

References (39)

1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88.
2. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-85.
3. 1. Am J Respir Crit Care Med 1997;155:852-7.
4. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:711-7.
5. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
6. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
7. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218-24.
8. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-24.
9. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60.
10. Dentener MA, Vernooy JH, Hendriks S, et al. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax 2005;60:114-9.
11. Majeed M, McQueen F, Yeoman S, et al. Relationship between serum hyaluronic acid level and disease activity in early rheumatoid arthritis. Ann Rheum Dis 2004;63:1166-8.
12. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996;98:2403-13.
13. Delvaux M, Henket M, Lau L, et al. Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma. Thorax 2004;59:111-5.
14. Bouma MG, Stad RK, van den Wildenberg FA, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-68.
15. Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-5.
16. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1035-9.
17. Ronchi MC, Piragino C, Rosi E, et al. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax 1996;51:1000-4.
18. Thomas RA, Green RH, Brightling CE, et al. The influence of age on induced sputum differential cell counts in normal subjects. Chest 2004;126:1811-4.
19. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005;60:293-300.
20. Bettiol J, Sele J, Henket M, et al. Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy 2002;57:1145-50.
21. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58:573-9.
22. Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 2003;22:94-9.
23. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997;10:1137-44.
24. Churg A, Wang RD, Tai H, et al. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004;170:492-8.
25. Liu LY, Swensen CA, Kelly EA, et al. The relationship of sputum eosinophilia and sputum cell generation of IL-5. J Allergy Clin Immunol 2000;106:1063-9.
26. Beeh KM, Beier J, Lerch C, et al. Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung 2004;182:369-77.
27. Fujihara M, Muroi M, Tanamoto K, et al. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003;100:171-94.
28. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
29. de Godoy I, Donahoe M, Calhoun WJ, et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996;153:633-7.
30. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5.
31. Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003;4:11.
32. Hurst JR, Wilkinson TM, Perera WR, et al. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005;127:1219-26.
33. van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9.
34. Vlahovic G, Russell ML, Mercer RR, et al. Cellular and connective tissue changes in alveolar septal walls in emphysema. Am J Respir Crit Care Med 1999;160:2086-92.
35. McDonald J, Hascall VC. Hyaluronan minireview series. J Biol Chem 2002;277:4575-9.
36. Song WD, Zhang AC, Pang YY, et al. Fibronectin and hyaluronan in bronchoalveolar lavage fluid from young patients with chronic obstructive pulmonary diseases. Respiration 1995;62:125-9.
37. Ohkawara Y, Tamura G, Iwasaki T, et al. Activation and transforming, growth factor-beta production in eosinophils by hyaluronan. Am J Respir Cell Mol Biol 2000;23:444-51.
38. Oertli B, Beck-Schimmer B, Fan X, et al. Mechanisms of hyaluronan-induced up-requlation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-kappa B and activating protein-1. J Immunol 1998;161:3431-7.
39. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.